ECM
ABBV icon

ETrade Capital Management’s AbbVie ABBV Stock Holding History

ETrade Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$7.38M Sell
84,267
-1,050
-1% -$98.9K 0.14% 74
2020
Q2 		$8.38M Sell
85,317
-6,209
-7% -$547K 0.17% 67
2020
Q1 		$6.97M Sell
91,526
-1,334
-1% -$114K 0.18% 67
2019
Q4 		$8.22M Buy
92,860
+2,149
+2% +$178K 0.18% 61
2019
Q3 		$6.87M Sell
90,711
-464
-0.5% -$31.8K 0.17% 68
2019
Q2 		$6.63M Buy
91,175
+13,389
+17% +$1.05M 0.18% 56
2019
Q1 		$6.27M Buy
77,786
+6,364
+9% +$521K 0.18% 58
2018
Q4 		$6.58M Buy
71,422
+15,431
+28% +$1.36M 0.21% 44
2018
Q3 		$5.29M Buy
55,991
+1,563
+3% +$148K 0.15% 68
2018
Q2 		$5.04M Sell
54,428
-26,797
-33% -$2.62M 0.16% 69
2018
Q1 		$7.69M Sell
81,225
-31,092
-28% -$3.42M 0.25% 38
2017
Q4 		$10.9M Sell
112,317
-6,622
-6% -$624K 0.35% 27
2017
Q3 		$10.6M Sell
118,939
-42,775
-26% -$3.26M 0.38% 24
2017
Q2 		$11.7M Sell
161,714
-1,811
-1% -$122K 0.45% 19
2017
Q1 		$10.7M Buy
163,525
+17,464
+12% +$1.1M 0.44% 21
2016
Q4 		$9.15M Buy
146,061
+3,538
+2% +$216K 0.42% 20
2016
Q3 		$8.99M Buy
142,523
+28,245
+25% +$1.83M 0.44% 20
2016
Q2 		$7.08M Buy
114,278
+11,424
+11% +$696K 0.37% 24
2016
Q1 		$5.88M Buy
102,854
+17,576
+21% +$980K 0.33% 27
2015
Q4 		$5.05M Sell
85,278
-1,171
-1% -$67.4K 0.3% 32
2015
Q3 		$4.7M Sell
86,449
-1,304
-1% -$84.9K 0.29% 30
2015
Q2 		$5.9M Sell
87,753
-3,389
-4% -$221K 0.35% 26
2015
Q1 		$5.33M Buy
91,142
+24,758
+37% +$1.5M 0.32% 30
2014
Q4 		$4.34M Buy
66,384
+934
+1% +$58.9K 0.26% 35
2014
Q3 		$3.78M Buy
65,450
+688
+1% +$38.2K 0.25% 38
2014
Q2 		$3.65M Buy
64,762
+5,465
+9% +$287K 0.24% 39
2014
Q1 		$3.05M Buy
59,297
+3,964
+7% +$200K 0.22% 45
2013
Q4 		$2.92M Buy
55,333
+10,865
+24% +$534K 0.23% 42
2013
Q3 		$1.99M Buy
44,468
+10,294
+30% +$456K 0.18% 49
2013
Q2 		$1.41M Buy
+34,174
New +$1.49M 0.15% 55

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

ETrade Capital Management's ABBV Position: Q3 2020 in Review

ETrade Capital Management reduced its AbbVie (ABBV) stake by 1.2% in Q3 2020, selling an estimated $98.9K and leaving 84,267 shares worth $7.38M. The position accounts for 0.14% of the portfolio, ranked #74.

ETrade Capital Management first reported a position in ABBV in Q2 2013 and has held it in 30 quarters since. The position peaked at $11.7M in Q2 2017. 2,367 funds tracked by Wall St. Rank hold ABBV as of Q3 2020.

  • ETrade Capital Management held 84,267 shares of AbbVie worth $7.38M as of Q3 2020.
  • ETrade Capital Management sold 1,050 AbbVie shares in Q3 2020, an estimated $98.9K.
  • AbbVie made up 0.14% of ETrade Capital Management's portfolio in Q3 2020, its #74 holding.
  • ETrade Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 30 quarters since.
  • ETrade Capital Management's AbbVie position peaked at $11.7M in Q2 2017.
  • 2,367 funds tracked by Wall St. Rank held AbbVie as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.